Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia

Shinichiro Okamoto

Research output: Contribution to journalReview articlepeer-review


Stem cell transplantation is an effective treatment for anemia associated with stem cell disorders such as severe aplastic anemia, myelodysplastic syndrome. Long-term survival rates after transplantation for those diseases range from less than 40% to more than 80%. The rates are significantly affected by recipient's age, HLA disparity between donor and recipient, sources of stem cells, and disease status. Results are best in younger patients transplanted with bone marrow from HLA-identical sibling at the early course of the diseases. The decision of whether and at what point to proceed to transplantation should be made early after diagnosis, based upon the consideration of a survival rate with reasonable quality of life expected with transplantation and other therapeutic approaches.

Original languageEnglish
Pages (from-to)575-583
Number of pages9
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number3
Publication statusPublished - 2008 Mar

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Allogeneic stem cell transplantation for severe aplastic anemia and myelodysplasia'. Together they form a unique fingerprint.

Cite this